Abstract 2657: Development of melanoma target-specific drug delivery system

Abstract

Abstract While many approved drugs are well-tolerated by most biological systems, numerous drugs could utilize advanced delivery systems to direct them where needed and minimize breakdown as they circulate through the body. We are exploring targeted delivery of doxorubicin using Nanotechnology-based Drug Delivery Systems (nanoDDSs). NanoDDSs have gained recent popularity but they do not posses inherent targeting capabilities. Nanoparticles and micelles can be modified in many ways allowing for specific targeted delivery. Over expression of CD44 in metastatic melanoma and a variety of tumor stem cells has made this receptor an ideal candidate for targeted drug delivery. The sequence to which CD44 binds within the type IV collagen triple helix has been identified as α1(IV)1263-1277. The incorporation of α1(IV)1263-1277 into drug loaded liposomes confers targeting selectivity against cancer cell lines that have CD44 receptors. Doxorubicin is one of the FDA approved drugs widely used for treatment of many types of cancers. The specificity of this drug can be enhanced by targeted delivery to the cancer cells, thereby minimizing deleterious side effects. In this study we present novel targeted doxorubicin-loaded liposomes and investigate the tumor cell selective localization and efficacy of the drug delivery system. Recent results on synthesis, structure and function, toxicity and selectivity will be presented. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2657.